Eventide Asset Management - Q4 2014 holdings

$916 Million is the total value of Eventide Asset Management's 106 reported holdings in Q4 2014. The portfolio turnover from Q3 2014 to Q4 2014 was 14.6% .

 Value Shares↓ Weighting
BLUE SellBLUEBIRD BIO INC$35,771,000
+151.9%
390,000
-1.4%
3.90%
+97.0%
AGIO SellAGIOS PHARMACEUTICALS INC$28,929,000
+9.3%
258,200
-40.2%
3.16%
-14.6%
PANW  PALO ALTO NETWORKS INC$25,200,000
+24.9%
205,6000.0%2.75%
-2.3%
RHT BuyRED HAT INC$23,190,000
+54.3%
335,400
+25.3%
2.53%
+20.6%
LOW BuyLOWES COS INC$22,876,000
+41.5%
332,500
+8.8%
2.50%
+10.6%
MGA BuyMAGNA INTL INC$22,781,000
+60.3%
209,600
+40.0%
2.49%
+25.4%
ABBV  ABBVIE INC$21,641,000
+13.3%
330,7000.0%2.36%
-11.4%
CELG  CELGENE CORP$21,253,000
+18.0%
190,0000.0%2.32%
-7.7%
FPRX BuyFIVE PRIME THERAPEUTICS INC$21,168,000
+133.3%
784,000
+1.3%
2.31%
+82.3%
MDVN SellMEDIVATION INC$21,028,000
-22.7%
211,100
-23.3%
2.30%
-39.6%
TRW  TRW AUTOMOTIVE HLDGS CORP$20,405,000
+1.6%
198,4000.0%2.23%
-20.6%
MIC BuyMACQUARIE INFRASTR CO LLCmembership int$19,564,000
+14.9%
275,200
+7.8%
2.14%
-10.2%
WBC BuyWABCO HLDGS INC$19,437,000
+45.3%
185,500
+26.1%
2.12%
+13.6%
DYAX  DYAX CORP$18,705,000
+38.9%
1,330,4000.0%2.04%
+8.6%
FEYE NewFIREEYE INC$18,177,000575,600
+100.0%
1.98%
LEA BuyLEAR CORP$18,076,000
+30.0%
184,300
+14.5%
1.97%
+1.6%
CMRX  CHIMERIX INC$16,853,000
+45.8%
418,6000.0%1.84%
+14.0%
DATA BuyTABLEAU SOFTWARE INCcl a$16,410,000
+32.8%
193,600
+13.8%
1.79%
+3.8%
SUNEQ BuySUNEDISON INC$15,503,000
+12.6%
794,600
+9.0%
1.69%
-12.0%
WAB BuyWABTEC CORP$15,180,000
+29.5%
174,700
+20.7%
1.66%
+1.2%
TRN NewTRINITY INDS INC$14,285,000510,000
+100.0%
1.56%
CPN BuyCALPINE CORP$14,103,000
+8.7%
637,300
+6.6%
1.54%
-15.0%
IPHI BuyINPHI CORP$13,812,000
+40.4%
747,400
+9.2%
1.51%
+9.8%
ACAD  ACADIA PHARMACEUTICALS INC$13,437,000
+28.2%
423,2000.0%1.47%
+0.3%
VCYT BuyVERACYTE INC$13,370,000
+49.5%
1,384,100
+50.9%
1.46%
+16.9%
LLTC  LINEAR TECHNOLOGY CORP$13,343,000
+2.7%
292,6000.0%1.46%
-19.7%
EOG  EOG RES INC$13,332,000
-7.0%
144,8000.0%1.46%
-27.3%
ASML BuyASML HOLDING N V$12,853,000
+38.7%
119,200
+27.1%
1.40%
+8.4%
NRG BuyNRG ENERGY INC$12,540,000
+62.4%
465,300
+83.6%
1.37%
+27.0%
SYNA BuySYNAPTICS INC$12,501,000
+6.5%
181,600
+13.2%
1.36%
-16.8%
TTPH SellTETRAPHASE PHARMACEUTICALS I$11,516,000
+91.8%
290,000
-3.6%
1.26%
+50.0%
NVAX  NOVAVAX INC$11,319,000
+42.2%
1,908,7000.0%1.24%
+11.2%
CBI BuyCHICAGO BRIDGE & IRON CO N V$10,999,000
-1.9%
262,000
+35.2%
1.20%
-23.3%
ININ  INTERACTIVE INTELLIGENCE GRO$10,643,000
+14.6%
222,2000.0%1.16%
-10.4%
LYB  LYONDELLBASELL INDUSTRIES N$10,630,000
-26.9%
133,9000.0%1.16%
-42.9%
PTLA  PORTOLA PHARMACEUTICALS INC$10,546,000
+12.0%
372,4000.0%1.15%
-12.4%
CCI  CROWN CASTLE INTL CORP$10,286,000
-2.3%
130,7000.0%1.12%
-23.6%
STML BuySTEMLINE THERAPEUTICS INC$10,245,000
+41.8%
600,500
+3.6%
1.12%
+10.8%
PCYC  PHARMACYCLICS INC$10,099,000
+4.1%
82,6000.0%1.10%
-18.6%
STKL  SUNOPTA INC$10,068,000
-1.8%
849,6000.0%1.10%
-23.3%
CXP  COLUMBIA PPTY TR INC$9,983,000
+6.2%
393,8000.0%1.09%
-16.9%
TSLA BuyTESLA MTRS INC$9,808,000
+53.7%
44,100
+67.7%
1.07%
+20.2%
BWA BuyBORGWARNER INC$9,451,000
+43.0%
172,000
+36.9%
1.03%
+11.8%
MEOH  METHANEX CORP$9,226,000
-31.4%
201,3000.0%1.01%
-46.4%
SPLK NewSPLUNK INC$9,220,000156,400
+100.0%
1.01%
UFS BuyDOMTAR CORP$8,792,000
+26.0%
218,600
+10.1%
0.96%
-1.4%
NLNK  NEWLINK GENETICS CORP$8,574,000
+85.6%
215,7000.0%0.94%
+45.1%
AYR  AIRCASTLE LTD$8,539,000
+30.6%
399,6000.0%0.93%
+2.1%
TEX  TEREX CORP NEW$8,462,000
-12.2%
303,5000.0%0.92%
-31.4%
VMW  VMWARE INC$8,070,000
-12.1%
97,8000.0%0.88%
-31.2%
P103PS  NPS PHARMACEUTICALS INC$8,009,000
+37.6%
223,9000.0%0.87%
+7.5%
LGND  LIGAND PHARMACEUTICALS INC$7,966,000
+13.2%
149,7000.0%0.87%
-11.5%
OII BuyOCEANEERING INTL INC$7,628,000
+12.7%
129,700
+24.8%
0.83%
-11.9%
CGNX BuyCOGNEX CORP$7,439,000
+84.7%
180,000
+80.0%
0.81%
+44.5%
MGNX BuyMACROGENICS INC$7,400,000
+85.4%
211,000
+10.5%
0.81%
+45.1%
KAR  KAR AUCTION SVCS INC$7,367,000
+21.0%
212,6000.0%0.80%
-5.4%
SGMO  SANGAMO BIOSCIENCES INC$7,339,000
+41.0%
482,5000.0%0.80%
+10.2%
XPO NewXPO LOGISTICS INC$6,541,000160,000
+100.0%
0.71%
CMRE  COSTAMARE INC$6,343,000
-19.8%
360,2000.0%0.69%
-37.3%
FC  FRANKLIN COVEY CO$6,110,000
-1.2%
315,6000.0%0.67%
-22.7%
CLDX  CELLDEX THERAPEUTICS INC NEW$5,269,000
+40.8%
288,7000.0%0.58%
+10.2%
PWR  QUANTA SVCS INC$5,190,000
-21.8%
182,8000.0%0.57%
-38.9%
SCTY  SOLARCITY CORP$4,760,000
-10.3%
89,0000.0%0.52%
-29.8%
AZPN  ASPEN TECHNOLOGY INC$4,500,000
-7.2%
128,5000.0%0.49%
-27.5%
AGTC  APPLIED GENETIC TECHNOL CORP$4,320,000
+13.0%
205,5000.0%0.47%
-11.6%
SRPT  SAREPTA THERAPEUTICS INC$3,749,000
-31.4%
259,1000.0%0.41%
-46.4%
CEMP  CEMPRA INC$3,616,000
+114.5%
153,8000.0%0.40%
+68.1%
ATRC  ATRICURE INC$3,040,000
+35.6%
152,3000.0%0.33%
+6.1%
TSRO NewTESARO INC$2,789,00075,000
+100.0%
0.30%
BMRN  BIOMARIN PHARMACEUTICAL INC$2,730,000
+25.3%
30,2000.0%0.30%
-2.0%
NTUS  NATUS MEDICAL INC DEL$2,703,000
+22.1%
75,0000.0%0.30%
-4.5%
CERN  CERNER CORP$2,515,000
+8.5%
38,9000.0%0.28%
-14.9%
NBIX BuyNEUROCRINE BIOSCIENCES INC$2,507,000
+65.6%
112,200
+16.1%
0.27%
+29.9%
TGTX  TG THERAPEUTICS INC$2,455,000
+48.4%
155,0000.0%0.27%
+16.0%
XLRN  ACCELERON PHARMA INC$2,419,000
+28.8%
62,1000.0%0.26%
+0.8%
RARE  ULTRAGENYX PHARMACEUTICAL IN$2,308,000
-22.5%
52,6000.0%0.25%
-39.4%
SUPN  SUPERNUS PHARMACEUTICALS INC$2,133,000
-4.5%
257,0000.0%0.23%
-25.3%
RGEN  REPLIGEN CORP$1,968,000
-0.6%
99,4000.0%0.22%
-22.1%
CSII BuyCARDIOVASCULAR SYS INC DEL$1,940,000
+55.8%
64,500
+22.4%
0.21%
+21.8%
HPTX  HYPERION THERAPEUTICS INC$1,831,000
-4.8%
76,3000.0%0.20%
-25.7%
AAVL BuyAVALANCHE BIOTECHNOLOGIES IN$1,750,000
+155.8%
32,400
+62.0%
0.19%
+101.1%
WPX NewWPX ENERGY INC$1,745,000150,000
+100.0%
0.19%
SAAS  INCONTACT INC$1,699,000
+1.1%
193,3000.0%0.18%
-21.3%
GWPH  GW PHARMACEUTICALS PLCads$1,692,000
-16.3%
25,0000.0%0.18%
-34.4%
INFI NewINFINITY PHARMACEUTICALS INC$1,689,000100,000
+100.0%
0.18%
ATHN  ATHENAHEALTH INC$1,617,000
+10.6%
11,1000.0%0.18%
-13.7%
TNDM BuyTANDEM DIABETES CARE INC$1,616,000
+50.5%
127,247
+59.1%
0.18%
+17.3%
SAGE  SAGE THERAPEUTICS INC$1,471,000
+16.2%
40,2000.0%0.16%
-9.0%
BRKR  BRUKER CORP$1,450,000
+6.0%
73,9000.0%0.16%
-17.3%
DRNA BuyDICERNA PHARMACEUTICALS INC$1,379,000
+70.0%
83,700
+31.4%
0.15%
+33.6%
INSM  INSMED INC$1,371,000
+18.6%
88,6000.0%0.15%
-6.8%
SLXP  SALIX PHARMACEUTICALS INC$1,356,000
-26.5%
11,8000.0%0.15%
-42.4%
FEIC  FEI CO$1,337,000
+19.8%
14,8000.0%0.15%
-6.4%
PCRX  PACIRA PHARMACEUTICALS INC$1,179,000
-8.5%
13,3000.0%0.13%
-28.3%
OMED  ONCOMED PHARMACEUTICALS INC$1,149,000
+14.9%
52,8000.0%0.12%
-10.7%
KPTI  KARYOPHARM THERAPEUTICS INC$1,123,000
+7.2%
30,0000.0%0.12%
-15.8%
RGLS NewREGULUS THERAPEUTICS INC$962,00060,000
+100.0%
0.10%
ACRX  ACELRX PHARMACEUTICALS INC$938,000
+22.6%
139,4000.0%0.10%
-4.7%
MDSO  MEDIDATA SOLUTIONS INC$902,000
+7.8%
18,9000.0%0.10%
-16.2%
QURE  UNIQURE NV$727,000
+60.8%
49,1000.0%0.08%
+25.4%
TFX  TELEFLEX INC$666,000
+9.4%
5,8000.0%0.07%
-14.1%
XOMA  XOMA CORP DEL$636,000
-14.7%
177,2000.0%0.07%
-33.7%
RPTP SellRAPTOR PHARMACEUTICAL CORP$316,000
-18.3%
30,000
-25.7%
0.03%
-37.0%
VSTM  VERASTEM INC$191,000
+7.3%
20,9000.0%0.02%
-16.0%
MEIP SellMEI PHARMA INC$109,000
-92.2%
25,582
-87.3%
0.01%
-93.8%
ZFGN NewZAFGEN INC$19,000600
+100.0%
0.00%
SNSS ExitSUNESIS PHARMACEUTICALS INC$0-91,800
-100.0%
-0.09%
AEGR ExitAEGERION PHARMACEUTICALS INC$0-20,000
-100.0%
-0.09%
SZYM ExitSOLAZYME INC$0-190,000
-100.0%
-0.20%
ARWR ExitARROWHEAD RESH CORP$0-114,700
-100.0%
-0.24%
CBST ExitCUBIST PHARMACEUTICALS INC$0-29,000
-100.0%
-0.27%
AKBA ExitAKEBIA THERAPEUTICS INC$0-166,200
-100.0%
-0.51%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2015-02-12
Signatures

The EDGAR filing(s) were signed by:

About Eventide Asset Management

Eventide Asset Management is a Boston-based investment firm that specializes in providing investment solutions to investors who are looking for long-term growth opportunities. The company was founded in 2008 by a group of experienced investment professionals who shared a common vision of creating a firm that would focus on investing in companies that are making a positive impact on society.

The company's investment philosophy is based on the belief that companies that are making a positive impact on society are more likely to be successful in the long run. Eventide's investment team conducts extensive research to identify companies that are aligned with this philosophy and have the potential to deliver strong returns over the long term.

The company's investment strategies are managed by a team of experienced professionals, including CEO Robin John, COO Finny Kuruvilla, and Chief Investment Officer, Dr. Finny Kuruvilla. The team has a proven track record of delivering strong returns to investors, and their investment strategies have been recognized by industry experts.

Eventide Asset Management offers a range of investment solutions, including mutual funds, separately managed accounts, and exchange-traded funds (ETFs). The company's funds are available to individual investors, financial advisors, and institutional investors.

Overall, Eventide Asset Management is a reputable investment firm that has a strong focus on investing in companies that are making a positive impact on society. The company's experienced investment team and proven track record make it a compelling option for investors who are looking for long-term growth opportunities.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
LOWES COS INC40Q3 20233.2%
PALO ALTO NETWORKS INC40Q3 20233.6%
ASML HOLDINGS NV40Q3 20231.9%
NEUROCRINE BIOSCIENCES INC40Q3 20231.1%
REPLIGEN CORP40Q3 20230.5%
VERACYTE INC38Q3 20231.5%
LAM RESEARCH CORP35Q3 20233.4%
XPO LOGISTICS INC34Q1 20233.8%
COLLEGIUM PHARMACEUTICAL INC34Q3 20232.6%
MAGNA INTL INC33Q4 20212.5%

View Eventide Asset Management's complete holdings history.

Latest significant ownerships (13-D/G)
Eventide Asset Management Q4 2014 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Cogent Biosciences, Inc.February 14, 20232,589,7783.7%
ESSA Pharma Inc.Sold outFebruary 14, 202300.0%
Freeline Therapeutics Holdings plcFebruary 14, 20235,920,7659.1%
KnowBe4, Inc.Sold outFebruary 14, 202300.0%
Praxis Precision Medicines, Inc.February 14, 20233,518,0627.5%
Prometheus Biosciences, Inc.February 14, 20231,032,9382.2%
SUTRO BIOPHARMA, INC.Sold outFebruary 14, 202300.0%
Vital Farms, Inc.Sold outFebruary 14, 202300.0%
Zymeworks Inc.Sold outFebruary 14, 202300.0%
Entasis Therapeutics Holdings Inc.February 14, 2022590,6021.2%

View Eventide Asset Management's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR/A2024-02-20
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View Eventide Asset Management's complete filings history.

Compare quarters

Export Eventide Asset Management's holdings